Therefore, the question arises whether targeting cofilin (by inhibiting its phosphorylation to strengthen its interaction with actin) might provide a potential to treat BWCFF‐mutation‐related brain disorders, such as epilepsy. Here, CFL1 is linked to brain disorder.